myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
NICE has developed a medtech innovation briefing (MIB) on myCOPD for self-management of chronic obstructive pulmonary disease
Search results
432 results
-
-
Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)
This document summarises the evidence base on suicide prevention: optimising medicines and reducing access to medicines as a means of suicide . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Shared decision making (KTT23)
This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .
-
Chemotherapy dose standardisation (KTT22)
This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Medicines optimisation in chronic pain (KTT21)
This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Safer insulin prescribing (KTT20)
This document summarises the evidence base on safer insulin prescribing . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)
This document summarises the evidence base on psychotropic medicines in people with learning disabilities whose behaviour challenges . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Multimorbidity and polypharmacy (KTT18)
This document summarises the evidence base on multimorbidity and polypharmacy . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)
This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)
This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants , including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Biosimilar medicines (KTT15)
The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Wound care products (KTT14)
This document summarises the evidence base on wound care products . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Non-steroidal anti-inflammatory drugs (KTT13)
The key therapeutic topic non-steroidal anti-inflammatory drugs has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Antimicrobial stewardship: prescribing antibiotics (KTT9)
This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Antipsychotics in people living with dementia (KTT7)
This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Hypnotics (KTT6)
This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Asthma: medicines safety priorities (KTT5)
This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Lipid-modifying drugs (KTT3)
This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)
This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Renin-angiotensin system drugs: dual therapy (KTT2)
The key therapeutic topic renin-angiotensin system drugs: dual therapy has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Minocycline (KTT11)
The key therapeutic topic minocycline has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Laxatives (KTT1)
The key therapeutic topic laxatives has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .
-
First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)
The key therapeutic topic first-choice antidepressant use in adults with depression or generalised anxiety disorder has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Schizophrenia: omega-3 fatty acid medicines (ESUOM19)
Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making
-
Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)
Summary of the evidence on melatonin for sleep disorders in children and young people with attention deficit hyperactivity disorder (ADHD)..
-
Postural hypotension in adults: fludrocortisone (ESUOM20)
Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making
-
Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
-
Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)
Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making
-
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
-
Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)
Summary of the evidence on perampanel for partial-onset seizures in epilepsy (in people aged 12 and over) to inform local NHS planning and decision-making
-
Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)
Summary of the evidence on guanfacine prolonged-release for attention deficit hyperactivity disorder (ADHD) to inform local NHS planning and decision-making
-
Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)
Summary of the evidence on aclidinium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making
-
Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)
Summary of the evidence on glycopyrronium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making
-
Significant haemorrhage following trauma: tranexamic acid (ESUOM1)
Summary of the evidence on tranexamic acid for significant haemorrhage (bleeding) after trauma (major injury) to inform local NHS planning and decision-making
-
External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)
Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning
-
Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)
Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making
-
Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)
Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making
-
Erectile dysfunction: avanafil (ESNM45)
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
-
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
-
Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)
Summary of the evidence on beclometasone/formoterol (Fostair) for treating chronic obstructive pulmonary disease (COPD)...
-
Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)
Summary of the evidence on the indacaterol/glycopyrronium (Ultibro Breezhaler) for relieving the symptoms of chronic obstructive pulmonary disease (COPD)..
-
Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)
Summary of the evidence on the fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler for asthma to inform local NHS planning and decision-making
-
Schizophrenia: lurasidone (ESNM48)
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
-
Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)
Summary of the evidence on umeclidinium/vilanterol combination inhaler (Anoro Ellipta) for treating chronic obstructive pulmonary disease (COPD)...
-
Erectile dysfunction: Alprostadil cream (ESNM50)
Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making
-
Asthma: tiotropium (Spiriva Respimat) (ESNM55)
Summary of the evidence on tiotropium (Spiriva Respimat) for treating asthma to inform local NHS planning and decision-making
-
Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)
Summary of the evidence on brinzolamide/brimonidine combination eye drops for treating glaucoma to inform local NHS planning and decision-making
-
Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)
Summary of the evidence on aclidinium/formoterol for chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making
-
Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)
Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making
-
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making